20 articles
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
Scientists discover how immune cells work together in unexpected ways, opening new paths for cancer therapy and transplant success.
HSCT therapy achieves drug-free remission in patients with treatment-resistant autoimmune conditions like lupus and rheumatoid arthritis.
Researchers modified red blood cells to teach the immune system tolerance, potentially ending need for harsh immunosuppressive drugs.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Researchers modified NK and T cells with special receptors that help them track down and infiltrate solid tumors more effectively.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
Chinese researchers test safer alternative to CAR-T therapy for lupus patients, achieving remission in 67% with minimal side effects.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
Scientists developed a breakthrough method to analyze thousands of immune cells simultaneously, revealing new insights into autoimmune diseases.
New antigen-specific tolerance approach could treat multiple sclerosis and related diseases without broad immunosuppression.
Engineered immune cells offer new hope for treating kidney diseases that resist standard therapies, potentially improving long-term health outcomes.
Virtual patient replicas built from multimodal data may slash trial costs, generate synthetic control arms, and predict treatment response in IBD.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
Revolutionary cancer treatment successfully treats treatment-resistant autoimmune disease, offering hope for severe cases.
Enhanced immune cells engineered with cytokines could overcome cancer's defenses and extend treatment options beyond blood cancers.
Dying cancer cells release GPX4 protein that prevents immune system activation, revealing new immunotherapy targets.
